OPKO Health Overview
OPKO Health Inc is a multinational corporation that researches, develops, and produces a variety of pharmaceutical technologies. The company pursues diagnostics, genetic testing, cancer treatment, fertility, growth hormone deficiency, and other areas of pharmaceutical research. OPKO Israel encompasses two main entities: OPKO Biologics and FineTech Pharmaceutical. OPKO Biologics, previously known as Prolor Biotech, is a clinical-stage company that concentrates on creating long-acting versions of therapeutic proteins and peptide drugs. They employ advanced technologies such as CTP, reversible PEGylation, and native stabilizer proteins. On the other hand, FineTech is involved in the development of high-value Active Pharmaceutical Ingredients (APIs) and devises methods to bypass patents, facilitating faster commercial progress for its pharmaceutical clients.
Latest News
growth-positive
Entera Bio Unveils Promising PK Data for First Oral GLP-2 Therapy
Entera Bio Ltd. recently presented promising pharmacokinetic data for its oral GLP-2 analog therapy for short bowel syndrome (SBS) at the ESPEN Congress. The therapy, developed in collaboration with OPKO Health, aims to offer a more convenient alternative to existing treatments like Gattex, which require daily injections. The data demonstrated significant pharmacological advantages, including a longer plasma half-life and higher peak plasma concentrations compared to current therapies. While still in preclinical development, the therapys potential to address a market worth nearly $800 million annually could drive positive investor sentiment. The collaboration with OPKO Health is crucial for advancing this innovative treatment.
Product StagePartners
growth-positive
Entera Bio Reports Positive PK Data for First-in-Class Oral GLP-2 Tablet Treatment for Patients with Short Bowel Syndrome at the 2025 ESPEN Congress
Entera Bio Ltd. announced promising preclinical data for its oral GLP-2 analog, OPK-8801003, at the ESPEN Congress. The data showed a significantly longer biological half-life and higher peak plasma levels compared to the only approved GLP-2 therapy, Gattex®. This development could transform treatment for 30,000 short bowel syndrome patients who currently rely on daily injections. Enteras collaboration with OPKO Health combines OPKOs GLP-2 analog with Enteras N-Tab™ platform, aiming to offer a less invasive, personalized dosing option. The preclinical studies demonstrated robust oral bioavailability, sustained exposure, and a favorable safety profile.
Product StagePartners
growth-positive
OPKO Health Reports Second Quarter 2025 Business Highlights and Financial Results
OPKO Health, Inc. reported its business highlights and financial results for the second quarter of 2025. Key developments include Mercks advancement of a Phase 1 Epstein-Barr virus vaccine trial in collaboration with OPKO, and ModeXs progress in its immuno-oncology portfolio with several clinical candidates. OPKO also presented promising preclinical data on its novel GLP-1/glucagon receptor dual agonist, OPK-88006, at the American Diabetes Associations Scientific Sessions. Additionally, OPKO is developing an oral tablet formulation of OPK-88006 in collaboration with Entera, which will be presented at the ENDO 2025 annual meeting. These advancements indicate a positive growth trajectory for OPKO Health.
Product StagePartners
growth-positive
OPKO Health’s (OPK) Oral GLP-2 Analog Selected for a Poster Presentation in Collaboration with Entera Bio (ENTX)
OPKO Health, Inc., in collaboration with Entera Bio Ltd., announced the selection of their Oral GLP-2 Analog for a poster presentation at the 47th European Society for Clinical Nutrition & Metabolism Congress. This new therapy, which combines OPKOs long-acting GLP-2 agonist with Enteras N-Tab technology, aims to treat short bowel syndrome by providing an oral alternative to the currently approved injectable treatment, GATTEX. The oral format could improve patient compliance and comfort. OPKO Health is an international biopharmaceutical company developing and selling medicines, including treatments for kidney disease. The collaboration with Entera Bio is seen as a positive development for OPKO Health.
Partners
growth-positive
OPKO Health and Entera Bio Announce Abstract on PK/PD of Oral GLP-2 Tablet for the Treatment of Short Bowel Syndrome Selected for 2025 ESPEN Congress
OPKO Health, Inc. and Entera Bio Ltd. have announced that their joint abstract on a first-in-class oral GLP-2 analog for treating Short Bowel Syndrome (SBS) will be presented at the ESPEN Congress in September 2025. This collaboration combines OPKOs GLP-2 agonist with Enteras N-Tab™ technology, aiming to offer an oral alternative to the currently available injectable therapy, GATTEX®. The oral format could improve patient compliance and personalize treatment. Entera Bio is a clinical-stage company focused on developing oral peptide therapies, with several programs in the pipeline, including treatments for osteoporosis and hypoparathyroidism. The collaboration with OPKO is part of Enteras strategy to transform standard care for significant unmet medical needs.
Product StagePartners
Team Members
1
Employees: 51-200
Web & Social Links
| Website | www.opko.com |
Locations
Ashlegan 15, Kiryat Gat, Israel
Miami, FL, USA
Photos & Videos
No files yet
OPKO Health Business
Business models
—
Product stage
—
Employees
51-200
Sector
—Target Customer
—Core Technology
—Tags (13)
biotechnologybiopharmaceuticaltherapeuticsfertilitymedical-devicesdrug-deliverylaboratoriesbiological-therapypharmaceuticalsdiagnosticsproteinsophthalmologypeptidesOPKO Health Financials
—
Total funding
—
Capital raised
—
Last funding
—
Funding stage
—
Total rounds
—
Investors
Public Offering / Exit
POEvent
Apr 2018
Undisclosed
OPKO Health Lifecycle
All Events
POEvent
Apr 2018
Undisclosed
OPKO Health News
16 articles
growth-positive
Entera Bio Unveils Promising PK Data for First Oral GLP-2 Therapy
Entera Bio Ltd. recently presented promising pharmacokinetic data for its oral GLP-2 analog therapy for short bowel syndrome (SBS) at the ESPEN Congress. The therapy, developed in collaboration with OPKO Health, aims to offer a more convenient alternative to existing treatments like Gattex, which require daily injections. The data demonstrated significant pharmacological advantages, including a longer plasma half-life and higher peak plasma concentrations compared to current therapies. While still in preclinical development, the therapys potential to address a market worth nearly $800 million annually could drive positive investor sentiment. The collaboration with OPKO Health is crucial for advancing this innovative treatment.
Product StagePartners
growth-positive
Entera Bio Reports Positive PK Data for First-in-Class Oral GLP-2 Tablet Treatment for Patients with Short Bowel Syndrome at the 2025 ESPEN Congress
Entera Bio Ltd. announced promising preclinical data for its oral GLP-2 analog, OPK-8801003, at the ESPEN Congress. The data showed a significantly longer biological half-life and higher peak plasma levels compared to the only approved GLP-2 therapy, Gattex®. This development could transform treatment for 30,000 short bowel syndrome patients who currently rely on daily injections. Enteras collaboration with OPKO Health combines OPKOs GLP-2 analog with Enteras N-Tab™ platform, aiming to offer a less invasive, personalized dosing option. The preclinical studies demonstrated robust oral bioavailability, sustained exposure, and a favorable safety profile.
Product StagePartners
growth-positive
OPKO Health Reports Second Quarter 2025 Business Highlights and Financial Results
OPKO Health, Inc. reported its business highlights and financial results for the second quarter of 2025. Key developments include Mercks advancement of a Phase 1 Epstein-Barr virus vaccine trial in collaboration with OPKO, and ModeXs progress in its immuno-oncology portfolio with several clinical candidates. OPKO also presented promising preclinical data on its novel GLP-1/glucagon receptor dual agonist, OPK-88006, at the American Diabetes Associations Scientific Sessions. Additionally, OPKO is developing an oral tablet formulation of OPK-88006 in collaboration with Entera, which will be presented at the ENDO 2025 annual meeting. These advancements indicate a positive growth trajectory for OPKO Health.
Product StagePartners
growth-positive
OPKO Health’s (OPK) Oral GLP-2 Analog Selected for a Poster Presentation in Collaboration with Entera Bio (ENTX)
OPKO Health, Inc., in collaboration with Entera Bio Ltd., announced the selection of their Oral GLP-2 Analog for a poster presentation at the 47th European Society for Clinical Nutrition & Metabolism Congress. This new therapy, which combines OPKOs long-acting GLP-2 agonist with Enteras N-Tab technology, aims to treat short bowel syndrome by providing an oral alternative to the currently approved injectable treatment, GATTEX. The oral format could improve patient compliance and comfort. OPKO Health is an international biopharmaceutical company developing and selling medicines, including treatments for kidney disease. The collaboration with Entera Bio is seen as a positive development for OPKO Health.
Partners
growth-positive
OPKO Health and Entera Bio Announce Abstract on PK/PD of Oral GLP-2 Tablet for the Treatment of Short Bowel Syndrome Selected for 2025 ESPEN Congress
OPKO Health, Inc. and Entera Bio Ltd. have announced that their joint abstract on a first-in-class oral GLP-2 analog for treating Short Bowel Syndrome (SBS) will be presented at the ESPEN Congress in September 2025. This collaboration combines OPKOs GLP-2 agonist with Enteras N-Tab™ technology, aiming to offer an oral alternative to the currently available injectable therapy, GATTEX®. The oral format could improve patient compliance and personalize treatment. Entera Bio is a clinical-stage company focused on developing oral peptide therapies, with several programs in the pipeline, including treatments for osteoporosis and hypoparathyroidism. The collaboration with OPKO is part of Enteras strategy to transform standard care for significant unmet medical needs.
Product StagePartners
growth-positive
OPKO Health (OPK) to Present OPK-88006 Data at ENDO 2025
OPKO Health, Inc., a diversified healthcare company, is set to present new data for its investigational oral OPK-88006 tablet treatment at ENDO 2025, in partnership with Entera Bio Ltd. The drug targets obesity, metabolic disorders, and fibrotic disorders, and is being developed as a novel dual agonist GLP-1/glucagon peptide. It will be available as a once-daily tablet and a weekly subcutaneous injection. The presentation will highlight the drugs pharmacologic effects and pharmacokinetic profile. This partnership and development are seen as growth-positive for OPKO Health, as it expands its pharmaceutical offerings in the metabolic therapy space.
Product StagePartners
growth-positive
OPKO Health and Entera Bio Abstract for First-in-Class Dual GLP-1/Glucagon Tablet Candidate for Patients with Obesity and Metabolic Disorders Selected for Presentation at the ENDO 2025 Annual Meeting
Entera Bio Ltd. and OPKO Health, Inc. have announced new data for their investigational oral OPK-88006 tablet treatment, which will be presented at the ENDO 2025 annual meeting. The companies are collaborating on a novel dual agonist GLP-1/glucagon peptide treatment for obesity and metabolic disorders, available as both a tablet and a weekly injection. Entera Bio is leveraging its proprietary N-Tab™ technology in this collaboration. They plan to file an Investigational New Drug application with the FDA later this year and are preparing for Phase 1 clinical studies. Entera Bio is a clinical-stage company focused on developing oral peptide therapies for unmet medical needs, with several programs in development, including treatments for osteoporosis and hypoparathyroidism.
Product StagePartners
growth-positive
Piper Sandler Reiterates a Buy Rating on Opko Health (OPK) With a $3 PT
Opko Health Inc. has been highlighted as a promising long-term penny stock. The company recently announced the sale of its BioReference laboratory testing businesses for up to $225 million, including a $192.5 million payout at closing and a potential $32.5 million performance-based earnout. Additionally, Opko Health has entered a collaboration with Entera Bio to advance oral GLP-1/glucagon tablet candidates for metabolic disorders and obesity. The company is also progressing with its ModeX immuno-oncology and immunology portfolio, with four potential clinical candidates in the pipeline. Despite these developments, some analysts suggest that AI stocks may offer greater upside potential.
AcquisitionPartners
Entera Bio Announces Collaboration with OPKO Biologics to Develop Oral Peptide Tablet Formulations for Obesity and Intestinal Malabsorption Syndromes | Entera Bio Ltd.
growth-positive
Opko jumps on Covid-19 diagnostic lab announcement
Opko Health Inc., controlled by former Teva Pharmaceutical Industries chairman Dr. Phillip Frost, is benefiting from the US policy change on COVID-19 testing. The companys share price has increased by 45% on the Tel Aviv Stock Exchange and Nasdaq after announcing its ability to conduct coronavirus tests. Opkos market cap is now $1.5 billion, reversing the downtrend in its share price. The US testing market has been opened to private companies, allowing leading laboratories like Labcorp and Quest to develop and conduct their own tests. Opko expects to offer its test within a week and is waiting for trial results for its growth hormone product. Opkos revenue in 2019 was $900 million, down 10% from 2018.
CustomersInvestment
growth-negative
Opko Health seeks $100m in NYSE public offering
Opko Health Inc. plans to raise up to $100 million in a public offering following the success of its growth hormone clinical trial. The growth hormone treatment was developed by Israeli company Prolor Biotech and will be commercialized by Pfizer. Opko is entitled to milestone payments of up to $275 million and royalties from the products marketing. Opkos share price has decreased by 7% on the Tel Aviv Stock Exchange. Opko acquired Prolor in 2013 for $480 million. The company operates the Bio Reference chain of laboratories and markets other products. The trial demonstrated that growth hormone treatment once a week was as effective as daily treatment for children with suspected growth hormone deficiency. Opkos market cap is currently NIS 3.9 billion.
Investment
growth-negative
Opko to activate shelf prospectus to raise $200m
Opko Health Inc. announced its intention to activate a shelf prospectus for a convertible senior notes issue of up to $200 million. The companys share price plunged 17% following the announcement. Opko will use the proceeds for its activity and to repay earlier debt. The company had $317 million in current liabilities and $43 million in cash at the end of Q3 2018. Opko also reported failure in a trial of its OPK-88004 product and positive news of approval for its new PSA test for detecting high risk of prostate cancer.
Investment
growth-negative
Pharma Company Opko Health Retracts Decision to Delist From the Tel Aviv Stock Exchange
Opko Health, Inc. has retracted its request to delist from the Tel Aviv Stock Exchange (TASE). The company, which is dually listed on the Nasdaq, initially submitted the request in early April. Opkos decision to remain on the TASE was influenced by the desire of its Israel-based investors and the importance of the listing to them. Opko is currently traded on the TASE with a market cap value of $1.7 billion. However, the companys stock has lost 61% of its value in the past 12 months.
Public Trading
growth-negative
Opko Health to delist from TASE
Opko Health, one of the largest companies on the Tel Aviv Stock Exchange, has announced its intention to cease being dual-listed and will only be traded on Nasdaq. The company, with a market cap of NIS 6 billion, did not provide an explanation for the move. Opko Health was previously seen as a successful example of dual listing by a US company in Tel Aviv, but most other dual-listed US biotech companies have experienced significant losses and have been delisted. Opko Healths decision to delist from TASE indicates a negative impact on the companys growth.
Public Trading
growth-positive
Opko turns Prolor into Israeli R&D, investment arm
Opko Health Inc. has renamed Prolor Biotech as Opko Biologics and plans to use it for R&D and seek new investment opportunities in Israel. Opko chairman, Phillip Frost, expressed confidence in the Israeli life sciences industry and the potential for innovative products. Opko expects significant progress in the development of its leading products, including the announcement of results for Rayaldy and the filing of a new drug application. They are also enthusiastic about the pending launch of their 4Kscore blood test for prostate cancer.
Acquisition
growth-positive
OPKO Health buys FineTech Pharmaceutical for $27.5m
FineTech Pharmaceutical Ltd. has been acquired by OPKO Health Inc. for $27.5 million in cash and shares. The acquisition will give OPKO the ability to develop complex and problematic active pharmaceutical ingredients (APIs) for sale or license to pharmaceutical companies. FineTech CEO Dr. Arie Gutman will stay on after the acquisition. The deal is due to be closed on December 29.
Acquisition
OPKO Health Team
Employee Info
| Employees (range) | 51-200 |
| Exact count | 59 |
| Team members | 1 |
Similar Companies
Similar companies data is computed dynamically and not stored in the entity profile. This section requires implementing a similarity query (e.g. by classification overlap, sector, district).
OPKO Health Internal
Recent Updates
Maor Perlov
· maor.perlov@sncentral.org · Manual · 2023-10-19 12:50:30.000000
Maor Perlov
· maor.perlov@sncentral.org · Manual · 2023-10-19 12:56:29.000000
Maor Perlov
· maor.perlov@sncentral.org · Manual · 2023-10-19 12:27:25.000000
Maor Perlov
· maor.perlov@sncentral.org · Manual · 2023-10-19 12:56:48.000000
Maor Perlov
· maor.perlov@sncentral.org · Manual · 2023-10-19 12:53:26.000000
Eran Levin
· eranl@sncentral.org · Automatic · 2024-12-05 14:20:15.000000
Eran Levin
· eranl@sncentral.org · Automatic · 2024-08-07 05:43:42.000000
Eran Levin
· eranl@sncentral.org · Automatic · 2024-12-05 14:52:29.000000
Maor Perlov
· maor.perlov@sncentral.org · Manual · 2023-10-19 12:26:53.000000
Maor Perlov
· maor.perlov@sncentral.org · Manual · 2023-10-19 12:50:30.000000
Eran Levin
· eranl@sncentral.org · Automatic · 2024-12-05 15:06:49.000000
Eran Levin
· eranl@sncentral.org · Automatic · 2024-08-07 05:07:48.000000
Ortal Wein
· ortalw@sncentral.org · Automatic · 2023-03-30 13:18:43.000000
Maor Perlov
· maor.perlov@sncentral.org · Manual · 2023-10-19 12:26:53.000000
Eran Levin
· eranl@sncentral.org · Automatic · 2024-01-25 07:55:41.000000
Eran Levin
· eranl@sncentral.org · Automatic · 2024-03-20 06:40:22.000000
Eran Levin
· eranl@sncentral.org · Automatic · 2025-02-06 12:44:01.000000
Maor Perlov
· maor.perlov@sncentral.org · Manual · 2023-10-19 12:56:29.000000
Maor Perlov
· maor.perlov@sncentral.org · Manual · 2023-10-19 12:27:25.000000
Maor Perlov
· maor.perlov@sncentral.org · Manual · 2023-10-19 12:26:53.000000
Maor Perlov
· maor.perlov@sncentral.org · Manual · 2023-10-19 12:56:29.000000
Maor Perlov
· maor.perlov@sncentral.org · Manual · 2023-10-19 12:26:53.000000
Ortal Wein
· ortalw@sncentral.org · Manual · 2023-03-30 13:18:43.000000
Maor Perlov
· maor.perlov@sncentral.org · Manual · 2023-10-19 12:56:29.000000
Maor Perlov
· maor.perlov@sncentral.org · Manual · 2023-10-19 12:54:29.000000
Maor Perlov
· maor.perlov@sncentral.org · Manual · 2023-10-19 12:56:29.000000
Maor Perlov
· maor.perlov@sncentral.org · Manual · 2023-10-19 12:56:29.000000
Maor Perlov
· maor.perlov@sncentral.org · Manual · 2023-10-19 12:27:29.000000
Ortal Wein
· ortalw@sncentral.org · Manual · 2023-03-30 13:18:43.000000
Eran Levin
· eranl@sncentral.org · Automatic · 2024-12-22 06:24:35.000000
Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.
Admin Info
| Confidence | 66/100 |
| Missing | product stage, sector, founding month, business model, video or image, funding rounds, markets, not claimed |
| BI Verification | Yamila Silbert |
| Crunchbase | opko-health |
| Phone | +97289300051 |
| Creator | Shmuel (Sam) Rausnitz |
| Creator email | shmuel.rausnitz@sncentral.org |
| Last updater | Maor Perlov |
| Updater email | maor.perlov@sncentral.org |
| Last update | 2023-10-19T00:00:00.000Z |
| Created | 2016-06-20T00:00:00.000Z |
| Status detail | Public on NASDAQ on Nov, 1995;Public on TASE on Aug, 2013; |